BioCentury | Jun 21, 2010
Company News

Helicon, Sapient Discovery LLC deal

...targets from Helicon. Sapient will receive an undisclosed upfront payment and is eligible for milestones. Helicon Therapeutics Inc....
BioCentury | Jun 14, 2010
Finance

Venture tracks

...Ventures as a senior advisor. Until 2005, he was Chairman and CEO of neurology company Helicon Therapeutics Inc....
BioCentury | Jul 28, 2008
Clinical News

Helicon, Inflazyme preclinical data

...II testing to treat age-associated memory impairment. Helicon licensed the compound from Inflazyme in 2003. Helicon Therapeutics Inc....
BioCentury | Oct 1, 2007
Company News

Biolipox, Inflazyme deal

...is in Phase I testing to treat inflammation. The PDE-4 program's IPL455,903 is partnered with Helicon Therapeutics Inc....
BioCentury | Apr 16, 2007
Clinical News

IPL455: Preliminary Phase IIa data

...IZP said it was told by partner Helicon that IPL455,903 failed to show significant effects on...
...of up to 90 mg. IZP expects to receive full data from Helicon this month. Helicon Therapeutics Inc....
BioCentury | Oct 9, 2006
Company News

PsychoGenics management update

...formerly adjunct associate professor at Cold Spring Harbor Laboratory and director of model systems at Helicon Therapeutics Inc. WIR...
BioCentury | Mar 6, 2006
Clinical News

IPL455: Phase IIa started

...4-week, double-blind, placebo-controlled, European Phase IIa trial in about 75 patients with age-associated memory impairment. Helicon Therapeutics Inc....
BioCentury | Dec 5, 2005
Clinical News

IPL455: Preliminary Phase Ib data

...and well tolerated at all doses tested up to 135 mg daily for 14 days. Helicon Therapeutics Inc....
BioCentury | May 16, 2005
Clinical News

IPL455: Phase I data

...acceptable pharmacokinetic profile. In particular, the companies noted that there was no evidence of emesis. Helicon Therapeutics Inc....
BioCentury | Apr 25, 2005
Company News

Inflazyme pulmonary, neurology news

...PDE-4 ) inhibitor, is partnered with Helicon Therapeutics Inc. (Uniondale, N.Y.) and is in Phase I trials. Helicon...
Items per page:
1 - 10 of 24
BioCentury | Jun 21, 2010
Company News

Helicon, Sapient Discovery LLC deal

...targets from Helicon. Sapient will receive an undisclosed upfront payment and is eligible for milestones. Helicon Therapeutics Inc....
BioCentury | Jun 14, 2010
Finance

Venture tracks

...Ventures as a senior advisor. Until 2005, he was Chairman and CEO of neurology company Helicon Therapeutics Inc....
BioCentury | Jul 28, 2008
Clinical News

Helicon, Inflazyme preclinical data

...II testing to treat age-associated memory impairment. Helicon licensed the compound from Inflazyme in 2003. Helicon Therapeutics Inc....
BioCentury | Oct 1, 2007
Company News

Biolipox, Inflazyme deal

...is in Phase I testing to treat inflammation. The PDE-4 program's IPL455,903 is partnered with Helicon Therapeutics Inc....
BioCentury | Apr 16, 2007
Clinical News

IPL455: Preliminary Phase IIa data

...IZP said it was told by partner Helicon that IPL455,903 failed to show significant effects on...
...of up to 90 mg. IZP expects to receive full data from Helicon this month. Helicon Therapeutics Inc....
BioCentury | Oct 9, 2006
Company News

PsychoGenics management update

...formerly adjunct associate professor at Cold Spring Harbor Laboratory and director of model systems at Helicon Therapeutics Inc. WIR...
BioCentury | Mar 6, 2006
Clinical News

IPL455: Phase IIa started

...4-week, double-blind, placebo-controlled, European Phase IIa trial in about 75 patients with age-associated memory impairment. Helicon Therapeutics Inc....
BioCentury | Dec 5, 2005
Clinical News

IPL455: Preliminary Phase Ib data

...and well tolerated at all doses tested up to 135 mg daily for 14 days. Helicon Therapeutics Inc....
BioCentury | May 16, 2005
Clinical News

IPL455: Phase I data

...acceptable pharmacokinetic profile. In particular, the companies noted that there was no evidence of emesis. Helicon Therapeutics Inc....
BioCentury | Apr 25, 2005
Company News

Inflazyme pulmonary, neurology news

...PDE-4 ) inhibitor, is partnered with Helicon Therapeutics Inc. (Uniondale, N.Y.) and is in Phase I trials. Helicon...
Items per page:
1 - 10 of 24